Year 2020, Volume 3 , Issue 1, Pages 14 - 17 2020-01-01

Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report

Sevil Alkan Çeviker [1] , Harun Yıldırım [2] , Emel Yıldız [3]


Probiotics are generally prescribed as an adjuvant in the treatment of antibiotic-associated diarrhea caused by Clostridium difficile and are considered a safe preparation. Recently, however, there have been reports in the literature about fungemia that develop after probiotic treatment, especially in immunosuppressive patients. In this article, we aimed to present a patient who received chemotherapy for gastric cancer, developed fungemia after Saccharomyces boulardii probiotic treatment and required intensive care.

Saccharomyces boulardii, Probiotic, Fungemia
  • Cesaro S, Chinello P, Rossi L, Zanesco L. 2000. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer, 8(6): 504-505.
  • Eren Z, Gürol Y, Sönmezoğlu M, Eren HŞ, Çelik G, Kantarcı G. 2014. Probiyotik tedavisinden sonra yaşlı bir hastada gelişen Saccharomyces cerevisiae fungemisi. Mikrobiyol Bul, 48(2): 351-355.
  • Fadhel M, Patel S, Liu E, Levitt M, Asif A. 2018. Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use. Med Mycol Case Rep, 23: 23–25.
  • Goldin BR, Gorbach SL. 2008. Clinicalindicationsforprobiotics: an overview. ClinInfectDis, 46(2): 96–100.
  • Guarner F, Sanders ME, Eliakim R, Fedorak R, Gangl A, Garisch J. 2017. Probiotics and prebiotics. World Gastroenterology Organisation Global Guidelines. https://www.worldgastroenterology.org (erişim tarihi: 09.09.2019).
  • Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JNV, Suttorp MJ, Johnsen B, Shanman R, Slusser W, Fu N, Smith A, Roth B, Polak J, Motala A, Perry T, Shekelle PG. 2011. Safety of probiotics to reduce risk and prevent or treat disease. Evid RepTechnol Assess (Full Rep), 200: 1-645.
  • Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard JP, Ricour C, Jacquemin JL, Berche P. 2000. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis, 19(1): 16-20.
  • Herbrecht R, Nivoix Y.2005. Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis, 40(11): 1635-1637.
  • Kara I, Yıldırım F, Özgen Ö, Erganiş S, Aydoğdu M, Dizbay M, Gürsel G, Kalkanci A. 2018. Saccharomyces cerevisiae fungemia after probiotic treatment in an intensive care unit patient. J Mycol Med, 28(1): 218-221.
  • Kutlu T. 2011.Pre ve Probiyotikler. Türk Ped Arş, 46 (Özel Sayı): 59-64.
  • Landaburu MF, López Daneri GA, Relloso S, Zarlenga LJ, Vinante MA, Mujica MT. 2019. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient. Rev Argent Microbiol, pii: S0325-7541(19)30051-3.
  • Lherm T, Monet C, Nougière B, Soulier M, Larbi D, Le Gall C, Caen D, Malbrunot C. 2002. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med, 28(6): 797-801.
  • Martin IW, Tonner R, Trivedi J, Miller H, Lee R, Liang X, Rotello L, Isenbergh E, Anderson J, Perl T, Zhang SX. 2017. Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use. Diagn Microbiol Infect Dis, 87(3):286-288.
  • Muñoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Pérez MJ, Sánchez-Somolinos M, Rincón C, Hortal J, Peláez T. 2005. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis, 40(11): 1625-1634.
  • Packey CD, Ciorba MA. 2010. Microbial influences on the small intestinal response to radiation injury. Curr Opin Gastroenterol, 26(2): 88-94.
  • Roy U, Jessani LG, Rudramurthy SM, Gopalakrishnan R, Dutta S, Chakravarty C, Jillwin J, Chakrabarti A. 2017. Seven cases of Saccharomyces fungaemia related to use of probiotics. Mycoses, 60(6): 375-380.
  • Santino I, Alari A, Bono S, Teti E, Marangi M, Bernardini A, Teggi A. 2014. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. Int J Immunopath Ph, 143–146.
  • URL1: Probiotics for gastrointestinal diseases. https://www.uptodate.com/contents/probiotics-for-gastrointestinal-diseases 2018, (erişim tarihi: 9 Eylül 2019).
Primary Language tr
Subjects General and Internal Medicine
Journal Section Articles
Authors

Orcid: 0000-0003-1944-2477
Author: Sevil Alkan Çeviker (Primary Author)
Institution: Kütahya Sağlık Bilimleri Üniversitesi, Evliya Çelebi Eğitim Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji, Kütahya.
Country: Turkey


Orcid: 0000-0002-9161-263X
Author: Harun Yıldırım
Institution: Kütahya Sağlık Bilimleri Üniversitesi, Evliya Çelebi Eğitim Araştırma Hastanesi, Acil Tıp Kliniği, Kütahya
Country: Turkey


Orcid: 0000-0003-4493-2099
Author: Emel Yıldız
Institution: Kütahya Sağlık Bilimleri Üniversitesi, Evliya Çelebi Eğitim Araştırma Hastanesi, Anesteziyoloji ve Reanimasyon, Kütahya
Country: Turkey


Dates

Publication Date : January 1, 2020

Bibtex @case report { bshealthscience591439, journal = {Black Sea Journal of Health Science}, issn = {}, eissn = {2619-9041}, address = {bsjhealthsci@blackseapublishers.com}, publisher = {Cem TIRINK}, year = {2020}, volume = {3}, pages = {14 - 17}, doi = {}, title = {Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report}, key = {cite}, author = {Alkan Çeviker, Sevil and Yıldırım, Harun and Yıldız, Emel} }
APA Alkan Çeviker, S , Yıldırım, H , Yıldız, E . (2020). Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report. Black Sea Journal of Health Science , 3 (1) , 14-17 . Retrieved from https://dergipark.org.tr/en/pub/bshealthscience/issue/49535/591439
MLA Alkan Çeviker, S , Yıldırım, H , Yıldız, E . "Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report". Black Sea Journal of Health Science 3 (2020 ): 14-17 <https://dergipark.org.tr/en/pub/bshealthscience/issue/49535/591439>
Chicago Alkan Çeviker, S , Yıldırım, H , Yıldız, E . "Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report". Black Sea Journal of Health Science 3 (2020 ): 14-17
RIS TY - JOUR T1 - Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report AU - Sevil Alkan Çeviker , Harun Yıldırım , Emel Yıldız Y1 - 2020 PY - 2020 N1 - DO - T2 - Black Sea Journal of Health Science JF - Journal JO - JOR SP - 14 EP - 17 VL - 3 IS - 1 SN - -2619-9041 M3 - UR - Y2 - 2019 ER -
EndNote %0 Black Sea Journal of Health Science Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report %A Sevil Alkan Çeviker , Harun Yıldırım , Emel Yıldız %T Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report %D 2020 %J Black Sea Journal of Health Science %P -2619-9041 %V 3 %N 1 %R %U
ISNAD Alkan Çeviker, Sevil , Yıldırım, Harun , Yıldız, Emel . "Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report". Black Sea Journal of Health Science 3 / 1 (January 2020): 14-17 .
AMA Alkan Çeviker S , Yıldırım H , Yıldız E . Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report. BSJ Health Sci.. 2020; 3(1): 14-17.
Vancouver Alkan Çeviker S , Yıldırım H , Yıldız E . Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report. Black Sea Journal of Health Science. 2020; 3(1): 17-14.